ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy

ÌÇÐÄ´«Ã½

NCCN Guidelines Insights: Prostate Cancer, Version 1.2023.

ÌÇÐÄ´«Ã½

NCCN Guidelines Insights: Prostate Cancer, Version 1.2023. Journal of the National Comprehensive Cancer Network : JNCCN Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D'Amico, A. V., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Guzzo, T., Ippolito, J. E., Kuettel, M. R., Lang, J. M., Lotan, T., McKay, R. R., Morgan, T., Netto, G., Pow-Sang, J. M., Reiter, R., Roach, M., Robin, T., Rosenfeld, S., Shabsigh, A., Spratt, D., Teply, B. A., Tward, J., Valicenti, R., Wong, J. K., Berardi, R. A., Shead, D. A., Freedman-Cass, D. A. 2022; 20 (12): 1288-1298

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.

View details for

View details for